Global Pediatric Genetic Disease Treatment Market, By Birth Defects (Cataracts, Cleft Lip or Palate, Congenital Heart Disease, Contractures, Diaphragmatic Hernia, Genital Malformations, Glaucoma, Misshapen Skull, Missing Fingers or Toes, Missing or Incomplete Arms or Legs, Spina Bifida), Chronic Disease (Bleeding Disorders, Childhood Cancers, Kidney or Urinary Tract Disease, Slow Growth or Short Stature, Cystic Fibrosis, Sickle Cell Disease, Thalassemia), Application (Inherited Disorder Testing, Pharmacogenetics Testing (Pgx), Human Leukocyte Antigen (Hla) Testing, Oncology Testing, Others) – Industry Trends and Forecast to 2030.
Pediatric Genetic Disease Treatment Market Analysis and Size
The rise in the prevalence of various kinds of cancer such as carcinoma and sarcoma across the globe acts as one of the major factors driving the growth of the global pediatric genetic disease treatment market. The increase in the adoption of unhealthy lifestyle patterns such as consumption of drugs and alcohol among youth and lack of exercise and improper diet increasing the incidences of chronic diseases among population accelerate the market growth. The rise in initiatives taken by public and private organizations for developing treatment and the growing need of several drugs for the treatment of the symptoms related to rare diseases further influence the market.
Data Bridge Market Research analyses that the global pediatric genetic disease treatment market which was USD 10.86 billion in 2022, is expected to reach USD 21.71 billion by 2030, and is expected to undergo a CAGR of 9.1% during the forecast period 2023-2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Pediatric Genetic Disease Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Birth Defects (Cataracts, Cleft Lip or Palate, Congenital Heart Disease, Contractures, Diaphragmatic Hernia, Genital Malformations, Glaucoma, Misshapen Skull, Missing Fingers or Toes, Missing or Incomplete Arms or Legs, Spina Bifida), Chronic Disease (Bleeding Disorders, Childhood Cancers, Kidney or Urinary Tract Disease, Slow Growth or Short Stature, Cystic Fibrosis, Sickle Cell Disease, Thalassemia), Application (Inherited Disorder Testing, Pharmacogenetics Testing (Pgx), Human Leukocyte Antigen (Hla) Testing, Oncology Testing, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa
|
|
Market Players Covered
|
Abbott (U.S.), Pfizer Inc. (U.S.), ELITechGroup (France), PerkinElmer Inc. (U.S.), Quest Diagnostics (U.S.), AutoGenomics (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Precipio (U.S.), Biosystems S.A. (Spain), Sarepta Therapeutics (U.S.), BioMarin (U.S.), GW Pharmaceuticals plc (U.K.), Vertex Pharmaceuticals Incorporated (U.S.), Shire (Ireland), Amgen Inc. (U.S.), Illumina, Inc. (U.S.), Invitae Corporation (U.S.), Progenity, Inc. (U.S.), Aetna Inc. (U.S.), and GeneDx (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Pediatric genetic disease treatment refers to the specialized medical approach and interventions focused on diagnosing, managing, and mitigating genetic disorders that manifest in children. These genetic disorders are caused by abnormalities in the DNA or genes, often present from birth, and they can result in a wide range of health challenges and developmental issues. The goal of pediatric genetic disease treatment is to provide targeted therapies, medications, and interventions to improve the quality of life for affected children and potentially offer a cure or significant symptom relief.
Global Pediatric Genetic Disease Treatment Market Dynamics
Drivers
- Technological Advancements in Diagnostic Tools and Treatment Modalities
The continuous advancement in diagnostic technologies, such as molecular imaging, next-generation sequencing, and liquid biopsies, is a significant driver for the global pediatric genetic disease treatment market. These innovations enable early and accurate diagnosis, as well as a better understanding of tumor characteristics. Moreover, advancements in treatment modalities, including targeted therapies, immunotherapies, and combination therapies, are contributing to improved outcomes and survival rates for patients with pediatric genetic diseases. These technological developments are likely to drive market growth by enhancing treatment efficacy and expanding the scope of therapeutic options.
- Increasing Incidence and Prevalence of Pediatric Genetic Disease
The rising incidence and prevalence of pediatric genetic diseases globally are driving the demand for effective treatment options. Factors such as lifestyle changes, exposure to environmental carcinogens, and a growing aging population contribute to the increasing burden of pediatric genetic diseases. This surge in cases necessitates the development of novel treatment approaches and the expansion of the treatment market. The growing patient pool presents an opportunity for market growth, encouraging research and development activities to address the unmet medical needs of individuals affected by pediatric genetic diseases.
Opportunity
- Growing Emphasis on Personalized Medicine and Precision Oncology
The rise of personalized medicine and precision oncology is revolutionizing cancer treatment, including pediatric genetic diseases. Tailoring treatments based on an individual's genetic makeup, tumor characteristics, and other relevant factors can significantly enhance treatment effectiveness. Personalized medicine allows for the identification of specific genetic mutations or biomarkers associated with pediatric genetic diseases, enabling targeted therapies that align with a patient's unique profile. With advancements in genetic profiling technologies and increasing understanding of tumor biology, there is a growing opportunity to develop customized treatment plans, optimize drug selection, and predict treatment responses. This personalized approach holds the potential to improve treatment outcomes, reduce adverse effects, and elevate the overall quality of life for pediatric genetic diseases patients
Restraint/Challenge
- High Cost of Advanced Treatment Modalities
The high cost associated with advanced treatment modalities for pediatric genetic diseases poses a significant restraint on the global market. Advanced therapies such as targeted treatments and immunotherapies often come with a substantial financial burden for patients, limiting their accessibility, especially in lower-income regions. In addition, healthcare systems and insurance coverage may not fully cover these high-cost treatments, creating a barrier to their widespread adoption. The cost factor acts as a restraint, hindering market growth and equitable access to cutting-edge treatments for pediatric genetic diseases.
This global pediatric genetic disease treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global pediatric genetic disease treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In July 2022, Pfizer Inc. received approval for Xalkori (crizotinib) by the U.S. FDA for the treatment of pediatric and adult patients with ALK-positive inflammatory myofibroblastic tumor (IMT). The recommended dose in adult patients is 250 mg and is to be administrated orally twice daily until disease progression stops. This approval is also expected to fuel the oral segment growth
- In February 2021, the U.S. FDA approved Sarepta Therapeutics’ AMONDYS 45 (casimersen injection) for the treatment of DMD. Based on route of administration, the global market is segmented into oral, injectable, and others
Global Pediatric Genetic Disease Treatment Market Scope
The global pediatric genetic disease treatment market is segmented on the basis of birth defects, chronic disease and application. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications
Birth Defects
- Cataracts
- Cleft Lip or Palate
- Congenital Heart Disease
- Contractures
- Diaphragmatic Hernia
- Genital Malformations
- Glaucoma
- Misshapen Skull
- Missing Fingers or Toes
- Missing or Incomplete Arms or Legs
- Spina Bifida
Chronic Disease
- Bleeding Disorders
- Childhood Cancers
- Kidney Or Urinary Tract Disease
- Slow Growth Or Short Stature
- Cystic Fibrosis
- Sickle Cell Disease
- Thalassemia
Application
- Inherited Disorder Testing
- Pharmacogenetics Testing (PGX)
- Human Leukocyte Antigen (HLA) Testing
- Oncology Testing
- Others
Global Pediatric Genetic Diseases Treatment Market Regional Analysis/Insights
The global pediatric genetic disease treatment market is analysed and market size insights and trends are provided by country, birth defects, chronic disease and application as referenced above.
The countries covered in the global pediatric genetic disease treatment market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa
North America dominates and register the highest growth rate in the p global pediatric genetic disease treatment market, due to rise in the surge in the approvals of products for the treatment and rise in the initiatives taken by the government and pharmaceutical organizations to spread awareness regarding the disease in this region.
Asia-Pacific is the expected to be the fastest growing region in terms of growth in the global pediatric genetic disease treatment market due to rise in the prevalence of pediatric genetic diseases in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the Market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global pediatric genetic disease treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global pediatric genetic disease treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global pediatric genetic disease treatment market. The data is available for historic period 2015-2020.
Competitive Landscape and Global Pediatric Genetic Diseases Treatment Market Share Analysis
The global pediatric genetic disease treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global pediatric genetic disease treatment market.
Some of the major players operating in the global pediatric genetic disease treatment market are:
- Pfizer Inc (U.S.)
- Abbott (U.S.)
- ELITechGroup (France)
- PerkinElmer Inc. (U.S.)
- Quest Diagnostics (U.S.)
- AutoGenomics (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Bio-Rad Laboratories, Inc. (U.S.)
- Precipio (U.S.)
- Biosystems S.A. (Spain)
- Sarepta Therapeutics (U.S.)
- BioMarin (U.S.)
- GW Pharmaceuticals plc (U.K.)
- Vertex Pharmaceuticals Incorporated (U.S.)
- Shire (Ireland)
- Amgen Inc. (U.S.)
- Illumina, Inc. (U.S.)
- Invitae Corporation (U.S.)
- Progenity, Inc. (U.S.)
- Aetna Inc. (U.S.)
- GeneDx (U.S.)
SKU-